AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced the presentation of new preliminary data from a Phase 1 trial of its first-in-class TDP-43 positron emission tomography (PET) tracer ACI-19626 showing increased uptake in the brains of patients with amyotrophic lateral sclerosis (ALS).
– Presentation at 2026 TDP43 Summit shows ACI-19626 detects TDP-43 pathology in patients with amyotrophic lateral sclerosis (ALS)
– Previously reported data also showed detection of TDP-43 in patients with genetically defined frontotemporal dementia (FTD)
– Underlines potential for precision medicine enabling early diagnosis and intervention in multiple neurodegenerative diseases